Condition
Clear Cell Renal Cell Cancer (ccRCC) clinical trials and research
As of November 12, 2026, Find a Trial lists 5 Clear Cell Renal Cell Cancer (ccRCC) clinical trials that are recruiting, at sites in 5 countries (most in United States (2), Australia (2), China (1)). By phase: Phase 1/2 (2), Phase 2 (1), Phase 3 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 5Countries
Newest Clear Cell Renal Cell Cancer (ccRCC) clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| CAIX-targeted 18F-T2 PET/CT imaging in solid tumors | — | Beijing, Beijing Municipality | Recruiting | Apr 29, 2026 |
| 177Lu-TLX250 for advanced relapsed or recurrent clear-cell kidney cancer | Phase 3 | Sydney, New South Wales and 4 other locations | Recruiting | Sep 29, 2025 |
| Zanzalintinib with a bone-strengthening agent for metastatic clear cell RCC with bone metastases | Phase 2 | San Francisco, California | Recruiting | Jun 29, 2025 |
| Assessing safety and efficacy of new treatments for advanced solid tumors | Phase 1/2 | Melbourne and 9 other locations | Recruiting | Jan 31, 2023 |
| Evaluating GI-101 with Pembrolizumab, Lenvatinib, or Radiotherapy in Advanced Solid Tumors | Phase 1/2 | New York, New York and 12 other locations | Recruiting | Jul 27, 2021 |
All recruiting trials (5)
-
CAIX-targeted 18F-T2 PET/CT imaging in solid tumors
This study tests a CAIX-specific radioactive tracer to see if PET/CT can help visualize solid tumors and checks safety and radiation exposure in adults with certain cancers.
-
177Lu-TLX250 for advanced relapsed or recurrent clear-cell kidney cancer
This will test whether 177Lu-TLX250, a CAIX-targeting radioligand, helps adults with CAIX-positive advanced or relapsed clear-cell kidney cancer who have had 2–3 prior therapies.
-
Zanzalintinib with a bone-strengthening agent for metastatic clear cell RCC with bone metastases
This phase 2 trial tests zanzalintinib plus a bone-strengthening agent in adults with metastatic clear cell renal cell cancer that has spread to bone and progressed after 1–3 prior therapies, including IO therapy.
-
Assessing safety and efficacy of new treatments for advanced solid tumors
This study is testing two new treatments for patients with advanced solid tumors to see if they are safe and effective.
-
Evaluating GI-101 with Pembrolizumab, Lenvatinib, or Radiotherapy in Advanced Solid Tumors
This study is testing a new treatment called GI-101, alone and with other therapies, to see if it can help people with advanced solid tumors.
Related topics
Quick answers
How many Clear Cell Renal Cell Cancer (ccRCC) clinical trials are recruiting right now?
5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 5 countries. The most sites are in United States (2 trials), Australia (2 trials), China (1 trial), South Korea (1 trial), France (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1/2: 2, Phase 2: 1, Phase 3: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.